These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8793708)

  • 1. An economic evaluation of universal vaccination against hepatitis B virus.
    Fenn P; Gray A; McGuire A
    J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
    Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
    [No Abstract]   [Full Text] [Related]  

  • 4. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
    Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
    Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness.
    Harris A; Yong K; Kermode M
    Aust N Z J Public Health; 2001 Jun; 25(3):222-9. PubMed ID: 11494989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK.
    Siddiqui MR; Gay N; Edmunds WJ; Ramsay M
    Vaccine; 2011 Jan; 29(3):466-75. PubMed ID: 21073988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
    Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
    Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales.
    Mangtani P; Hall AJ; Normand CE
    J Epidemiol Community Health; 1995 Jun; 49(3):238-44. PubMed ID: 7629457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic evaluation of various hepatitis B vaccination Strategies in Switzerland].
    Zurn P; Danthine JP
    Soz Praventivmed; 1998; 43 Suppl 1():S61-4, S134-7. PubMed ID: 9833269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of the Polish hepatitis B prevention programme.
    Wiewióra-Pilecka D
    Vaccine; 2000 Feb; 18 Suppl 1():S52-4. PubMed ID: 10683548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence.
    Rafia R; Dodd PJ; Brennan A; Meier PS; Hope VD; Ncube F; Byford S; Tie H; Metrebian N; Hellier J; Weaver T; Strang J
    Addiction; 2016 Sep; 111(9):1616-27. PubMed ID: 26990598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations.
    Margolis HS; Coleman PJ; Brown RE; Mast EE; Sheingold SH; Arevalo JA
    JAMA; 1995 Oct; 274(15):1201-8. PubMed ID: 7563509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of a 2-dose hepatitis B vaccination regimen for adolescents.
    Levaux HP; Schonfeld WH; Pellissier JM; Cassidy WM; Sheriff SK; Fitzsimon C
    Pediatrics; 2001 Aug; 108(2):317-25. PubMed ID: 11483794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
    Sun PP; Zhang SX; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
    [No Abstract]   [Full Text] [Related]  

  • 18. An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: an analytic decision approach to cost-effectiveness.
    Vimolket T; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2005 May; 36(3):693-9. PubMed ID: 16124440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
    Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
    Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates.
    Jacobs RJ; Rosenthal P; Meyerhoff AS
    Vaccine; 2004 Mar; 22(9-10):1241-8. PubMed ID: 15003653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.